Dry Eye Disease (DED), Meibomian Gland Dysfunction
Conditions
Brief summary
The goal of this clinical trial is to understand novel treatment methods for meibomian gland dysfunction (MGD)-associated dry eye disease (DED) by comparing two treatment modalities- intense pulsed light (IPL) and thermal pulsation therapy (TPT), to find out the difference of their therapeutic mechanisms and treatment effects, so that eye doctors can give more precise advice to the patients when making treatment decisions. The main questions it aims to answer are: * What subtype of meibomian gland dysfunction (MGD) better responds to which treatment modality? * How long do the treatment effects last? Researchers will compare each group (IPL and TPT) to a control group treated with eyedrops. \* Do combined treatment of IPL or TPT with eyedrops show better outcomes than only eyedrops? Participants will: * Receive different treatment for 2 months according to the group they were randomly allocated to. * Visit the clinic for checkups after 1 and 3 months after completing the treatment sessions.
Interventions
DEVICEIntense pulsed light
Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.
Thermal pulsation therapy utilizes local heating and massage on the eyelids.
DRUGOcular lubricant
Ocular lubricants moisturize the ocular surface.
Sponsors
Nobel Eye Institute
National Science and Technology Council, Taiwan
National Health Research Institutes, Taiwan
National Yang Ming Chiao Tung University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* individuals diagnosed with meibomian gland dysfunction (MDG)-associated dry eye disease (DED) that are suitable for intense pulsed light (IPL) and thermal pulsation therapy (TPT)
Exclusion criteria
* ocular surgery or trauma in the recent 3 months * ocular infection * eyelid abnormalities (e.g., entropion, ectropion, lagophthalmos, severe ptosis or trichiasis) * blepharospasm * eyelid tumor * severe meibomian gland atrophy * allergic to topical anesthetics * sunbathe in recent one month * periocular fillers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ocular Surface Disease Index (OSDI) questionnaire | From enrollment to the end of post-treatment follow-up at 5 months. | Ocular Surface Disease Index (OSDI) questionnaire was assessed by participants in each follow-ups. |
Countries
Taiwan
Outcome results
None listed